TYRA Tyra Biosciences, Inc. Insider Trading

Director MORE ROBERT J sells 246,871 shares of TYRA at $20.25; still holds 3.83M shares post-transaction

Director MORE ROBERT J sold 246,871 shares representing 6.1% of his pre-transaction holdings during a period of strong momentum—the stock is up 53.9% over 30 days and 70.0% over 90 days. The sale occurred at $20.25, below the current price of $21.90 and 1.6% below the 52-week high of $22.26, suggesting execution during an elevated but not peak valuation. The company remains unprofitable with net income of $-29,868,000.00 over its most recent full fiscal year, which contrasts with the stock's recent rally. With 3,833,425 shares retained, the director maintains substantial exposure, indicating the sale reduced position size rather than representing a full exit.

COO Bensen Daniel sells 125,589 shares over two days for $2.0M at $16.17 avg, reducing stake 42.3%; TYRA unprofitable with -$29.9M net income

Bensen Daniel, Chief Operating Officer, executed 2 separate sales totaling 125,589 shares for $2,030,923.43, reducing his holdings from 296,570 shares to 170,981 shares (a 42.3% reduction in stake). The transactions occurred on 2025-11-18 and 2025-11-19 at a blended average price of $16.17, within 0.7% of the 52-week high of $16.73. At the same ticker, Daniel has made 5 prior trades, all sales, concentrated in November 2025 (four recent sales with outcomes not yet measurable). His cross-ticker track record shows a 90-day well-timed rate of 57.14% across 11 prior sells, but his single prior measurable sale at TYRA (2024-02-06) resulted in a positive 90-day return of +1.4%, indicating the stock rose after that sale. The company remains unprofitable with net income of -$29,868,000.00 over its most recent full fiscal year, creating a gap between the stock's recent momentum (30-day: +10.6%, 90-day: +42.0%) and fundamental financial performance.

COO Bensen Daniel sold 131,411 shares at $16.04 blended average for $2.1M, reducing holdings 30.7%

Bensen Daniel, Chief Operating Officer of Tyra Biosciences, executed 4 separate sales totaling 131,411 shares for $2,108,066.97 over a 5-day window (Nov 13-17, 2025), reducing his stake by 30.7% to 296,570 shares. The sales occurred at prices ($16.00–$17.07) near the 52-week high of $16.73, and the stock has rallied 9.7% over the past 30 days and 55.9% over 90 days before this transaction. Across his prior 5 trades at TYRA, Bensen's timing has been mixed: 2 of 5 prior sells subsequently declined beyond 90 days, while 3 produced gains, suggesting no consistent pattern of foresight at this ticker. The company is unprofitable (net income $-29,868,000.00 for its most recent full fiscal year), and the liquidation's scale and timing relative to recent strong price performance warrants attention to whether material developments are expected.

RA Capital Management bought 163,287 shares across 3 trades for $1,664,700.49 at TYRA, bringing stakes to 10,259,291 shares.

RA Capital Management, a director of Tyra Biosciences, executed 3 separate purchases totaling 163,287 shares for $1,664,700.49 at an average price of $10.19 between June 12–16, 2025, increasing its shareholding by 1.6% to 10.26M shares. The company is unprofitable with a net loss of $28,147,000 for its most recent full fiscal year, and the stock is trading at $10.22, down 64.3% from its 52-week high of $28.61. At the same ticker, the insider's prior buy on 2024-11-08 generated a 90-day return of -19.0%, and earlier purchases at this stock dated 2025-06-04, 2025-06-05, and 2025-06-09 are too recent to assess outcomes. The cumulative activity—four buys in June alone plus one in November—suggests sustained accumulation despite the unprofitable fundamentals and substantial year-to-date decline, providing a data point for monitoring whether this level of insider engagement correlates with operational or strategic developments.

RA Capital Management Director acquires 186,850 shares of TYRA at $10.19 ($1.9M); second purchase in four days within unprofitable biotech.

RA Capital Management, as a Director at Tyra Biosciences, purchased 186,850 shares at $10.19 for $1,904,001.50 on 2025-06-09, expanding holdings to 10,096,004 shares. This represents the entity's second buy at TYRA in as many days (following a June 4 purchase), totaling two sequential acquisitions within a 5-day window. The stock is trading at $10.18, near the transaction price, but has declined 64.4% from its 52-week high of $28.61 and 5.2% over the prior 90 days. Across RA Capital's broader open-market history, prior buys have averaged a -0.4% return at 90 days with a 46.15% win rate, while the entity's single prior sale achieved a 0.00% well-timed rate—neither pattern suggests consistent favorable execution. At TYRA specifically, a November 2024 purchase declined 19.0% over 90 days. The repeated buying against recent price weakness in an unprofitable company with $-28,147,000 in net income warrants attention to the underlying catalysts driving these successive acquisitions.

RA Capital Management bought 1,211,198 shares (1.21M) for $11,751,303.68 across two June transactions at blended average $9.70, increasing holdings 13.9% to 9.91M shares.

RA Capital Management filed two separate purchases totaling 1,211,198 shares for $11,751,303.68 at an average price of $9.70, expanding its TYRA stake by 13.9% to 9,909,154 shares. The timing is notable given the stock's current price of $10.55 is -63.1% from its 52-week high of $28.61, and the transactions occurred during a recent 30-day window of +15.6% price appreciation. However, the insider's same-ticker history at TYRA shows a prior November 2024 buy that delivered -19.0% return over 90 days, and cross-ticker track record shows 0 of 1 prior TYRA buys were well-timed at the 90-day mark. The company remains unprofitable with net income of $-28,147,000.00, which provides fundamental context for the depressed valuation relative to the 52-week range.

RA Capital Management bought 1,220,681 shares of TYRA at $16.25 on 2024-11-08, increasing holdings by 16.3% to 8.70M shares

RA Capital Management, as a director of Tyra Biosciences, purchased 1,220,681 shares for $19,836,066.25, expanding its stake by 16.3% at a transaction price of $16.25. The stock currently trades at $15.74, down 45.0% from its 52-week high of $28.61 and down 28.5% over the prior 30 days. The company is unprofitable with a net loss of $24,016,000 in its most recent full fiscal year. While RA Capital's cross-ticker open-market history shows 18 prior buys with an average 90-day return of +290.6%, that track record does not predict accuracy at this specific ticker, and the substantial recent price decline combined with ongoing losses presents material downside context for this accumulation.

Director Kjellson sells 74.6K shares at $17.18–$17.32 for $1.3M as stock falls 43.7% from 52-week high

Kjellson Nina S, a director at Tyra Biosciences, executed 4 separate sales totaling 74,582 shares for $1,284,133.32 on November 6–7, 2024, at blended average price of $17.22. The sales reduced her holdings from 523.8K shares to 449.3K shares (a 14.2% reduction). The timing is notable: the stock is now trading at $16.11, down 43.7% from its 52-week high of $28.61, and has declined 24.3% over the past 30 days. The company is unprofitable with net income of $-24.0M over its most recent full fiscal year. These sales occurred just days after Kjellson executed 4 additional sales on October 31 and November 1, 2024, indicating a pattern of liquidation during a period of significant stock price weakness.

CFO Alan Fuhrman buys 9,500 shares of TYRA at $16.00; holdings triple to 12,849 shares amid -42.7% decline from 52-week high.

CFO Alan Fuhrman purchased 9,500 shares at $16.00, increasing his holdings by 283.7% from 3,349 to 12,849 shares. The stock is currently trading at $16.39, down 42.7% from its 52-week high of $28.61 and down 26.8% over the prior 30 days. The company reported a net loss of $18.7M in its most recent full fiscal year. The substantial increase in the CFO's position size during a period of significant price weakness and ongoing unprofitability creates a material information event warranting investor examination.

Director Nina S Kjellson sold 138,711 shares for $2,282,656.07 across 8 separate transactions from Oct 30 to Nov 1, reducing holdings 23.2%.

Director Kjellson executed 8 separate sales totaling 138,711 shares for $2,282,656.07 over three consecutive business days (Oct 30–Nov 1), at prices ranging from $16.17 to $17.16 and a blended average of $16.46. The transactions reduced her holdings from 597,217 to 458,506 shares, a 23.2% reduction in her position. This concentrated liquidation occurred while TYRA trades at $16.39 (current price), down 42.7% from its 52-week high of $28.61 and down 26.8% over the past 30 days, in a context where the company reported a full-year net loss of $18,702,000. The multi-day, multi-tranche structure and substantial reduction in absolute holdings warrant investor attention to the underlying business conditions that prompted a director to divest a significant portion of her stake.